Join us on October 2nd for a fireside chat with Jason Lettiere (Healthcare Investment, Bank of America Merrill Lynch) and learn about what the investment community wants from entrepreneurial science. What is your scientific excellence worth, and who would value it most?
The event will be hosted by Perspectum Diagnostics, Oxford’s fastest-growing spinout, at the Said Business School.
In this candid conversation you'll get the perspective of an Oxford-grown scientific success and a transatlantic view on the value of your scientific/medical training in business. This is a unique opportunity to hear first-hand about the skills and mindset of a resarcher at the centre stage of innovation as the speakers share their personal stories and discuss:
- The pros and cons of academic entrepreneurs from Wall Street
- Common pitfalls in translating science
- What investment partners make sense at what stage?
The session will begin with refreshments and time to network with fellow innovative thinkers and hosts. The evening will be brought to a close with an opportunity to informally ask the speakers any burning questions you may have.
Registration, refreshments and networking
Final remarks and close
Rajarshi Banerjee is CEO of Perspectum, which he co-founded in 2012, and now employs 110 people across Oxford, Singapore and San Francisco. He has worked in the National Health Service since 2002 and trained in cardiology, public health and internal medicine in London and Oxford. He developed the MR techniques for rapid non-invasive liver assessment during his PhD in Oxford, and commercialised these through Perspectum as LiverMultiScan, which is now FDA cleared and used in over 200 sites.
Rajarshi continues to work as an Honorary Consultant Physician in Oxford, with research into the phenotyping of metabolic and liver disease in adults and children. He has many years of experience in running clinical trials and working in multidisciplinary scientific teams to develop applications for precision medicine.
Jason is currently an Associate on the Healthcare Investment Banking team at Bank of America Merrill Lynch. Prior to joining Bank of America, Jason spent over four years at Intercept Pharmaceuticals where, as a member of the Business Development & Corporate Strategy team, he supported senior management in strategic planning, opportunity assessment and capital raising. Prior to Intercept, he spent three years in healthcare investment banking at boutique advisory firms. His transaction experience includes mergers & acquisitions, initial public offerings and other equity and debt financings in the biopharmaceuticals sector.
Jason received a B.S. in Economics and Finance from Bentley University.
Thursday, December 03rd 2020
12:53 – 12:53 (GMT)